A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
Blood. 2020.
PMID: 32731259
Free PMC article.
Clinical Trial.